Search

Your search keyword '"Gianni L."' showing total 1,300 results

Search Constraints

Start Over You searched for: Author "Gianni L." Remove constraint Author: "Gianni L."
1,300 results on '"Gianni L."'

Search Results

1. Comparison between two therapeutic approaches to post-operative pain in urological surgery Psychological and pharmacological aspects

2. Final results of the real-life observational VICTOR-6 study on metronomic chemotherapy in elderly metastatic breast cancer (MBC) patients

3. Multiplexed high-throughput immune cell imaging in patients with high-risk triple negative early breast cancer: Analysis from the International Breast Cancer Study Group (IBCSG) Trial 22-00

6. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

7. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

8. Factors influencing 5-year persistence to adjuvant endocrine therapy in young women with breast cancer

9. Tumour ecosystem and molecular dynamics in clinical triple-negative breast cancer depend on the chemotherapy regimen

10. Core and edge modeling of JT-60SA H-mode highly radiative scenarios using SOLEDGE3X-EIRENE and METIS codes.

11. Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study

12. Final results of the real-life observational VICTOR-6 study on metronomic chemotherapy in elderly metastatic breast cancer (MBC) patients

13. Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study

14. Fertility concerns, preservation strategies and quality of life in young women with breast cancer: Baseline results from an ongoing prospective cohort study in selected European Centers

15. UDINEE: Evaluation of Multiple Models with Data from the JU2003 Puff Releases in Oklahoma City. Part I: Comparison of Observed and Predicted Concentrations

16. UDINEE: Evaluation of Multiple Models with Data from the JU2003 Puff Releases in Oklahoma City. Part II: Simulation of Puff Parameters

19. Superconducting gap anisotropy of LuNi2B2C thin films from microwave surface impedance measurements

22. Employment trajectories of young women with breast cancer: an ongoing prospective cohort study in Italy and Switzerland

23. P120 Cardiac safety of pertuzumab, trastuzumab and standard chemotherapy as neoadjuvant treatment for HER2 positive breast cancer: real world data from NeoPowER trial

24. Breast cancers with high proliferation and low ER-related signalling have poor prognosis and unique molecular features with implications for therapy

25. Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer

32. 216MO A randomized phase II trial of metronomic oral vinorelbine plus cyclophosphamide and capecitabine (VEX) vs weekly paclitaxel (P) as first- or second-line treatment in patients (pts) with ER+/HER2- metastatic breast cancer (MBC): The METEORA-II trial (IBCSG 54-16)

34. Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study

35. Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial

37. Agriculture in Marginal Areas: Reintroduction of Rye and Wheat Varieties for Breadmaking in the Antrona Valley

39. Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies

40. Toward High-Value, Cost-Conscious Care – Supporting Future Doctors to Adopt a Role as Stewards of a Sustainable Healthcare System

42. Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab

44. Immune milieu associated with PD-L1 status in TNBC is dependent on time of biomarker assessment and treatment received: A secondary analysis of the NeoTRIPaPDL1 trial

45. Overall survival in the OlympiA phase Ill trial of adjuvant olaparib in patients with germime pathogenic variants in BRCA1/2 and high-risk, early breast cancer

48. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study

Catalog

Books, media, physical & digital resources